Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List
Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.